Apellis Pharmaceuticals, INC. (APLS) — SEC Filings

Overview

Apellis Pharmaceuticals, INC. (APLS) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Oct 30, 2025: Apellis Pharmaceuticals, Inc. reported a significant turnaround, achieving a net income of $215.7 million for the three months ended September 30, 2025, compared to a net loss of $57.4 million in the same period of 2024. For the nine months ended September 30, 2025, the company posted a net income o

Sentiment Summary

Across 32 filings, the sentiment breakdown is: 1 bullish, 30 neutral, 1 mixed. The dominant filing sentiment for Apellis Pharmaceuticals, INC. is neutral.

Filing Type Overview

Apellis Pharmaceuticals, INC. (APLS) has filed 1 3, 6 10-Q, 10 8-K, 2 DEF 14A, 2 10-K, 4 SC 13G, 6 SC 13G/A, 1 10-K/A with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (32)

• 3 Filing — 3 · Apr 6, 2026
• Apellis Swings to Profit on Soaring Licensing Revenue — 10-Q · Oct 30, 2025 Risk: medium
  Apellis Pharmaceuticals, Inc. reported a significant turnaround, achieving a net income of $215.7 million for the three months ended September 30, 2025, compare
• Apellis Widens Q2 Loss Amid SYFOVRE Commercial Push — 10-Q · Jul 31, 2025 Risk: high
  Apellis Pharmaceuticals, Inc. reported a net loss of $179.9 million for the three months ended June 30, 2025, a significant increase from the $145.7 million net
• Apellis Pharmaceuticals Enters Material Definitive Agreement — 8-K · Jul 1, 2025 Risk: medium
  On July 1, 2025, Apellis Pharmaceuticals, Inc. entered into a material definitive agreement. The filing does not disclose the specific nature or terms of this a
• Apellis Pharmaceuticals Files 8-K on Shareholder Vote Matters — 8-K · Jun 4, 2025 Risk: low
  Apellis Pharmaceuticals, Inc. filed an 8-K on June 4, 2025, reporting on matters submitted to a vote of security holders as of June 3, 2025. The filing does not
• Apellis Pharmaceuticals Q1 2025 10-Q Filing — 10-Q · May 7, 2025 Risk: low
  Apellis Pharmaceuticals, Inc. reported its first quarter 2025 results, ending March 31, 2025. The company's financial statements reflect various assets and liab
• Apellis Pharma DEF 14A: Executive Compensation Details — DEF 14A · Apr 23, 2025 Risk: low
  Apellis Pharmaceuticals, Inc. filed a DEF 14A on April 23, 2025, detailing executive compensation and equity awards for the fiscal years ending December 31, 202
• Apellis Pharmaceuticals Announces Board and Executive Changes — 8-K · Apr 21, 2025 Risk: medium
  On April 17, 2025, Apellis Pharmaceuticals, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The fi
• Apellis Pharmaceuticals Files 2024 10-K — 10-K · Feb 28, 2025 Risk: medium
  Apellis Pharmaceuticals, Inc. filed its 2024 10-K on February 28, 2025, reporting on its fiscal year ending December 31, 2024. The company, incorporated in Dela
• Apellis Pharmaceuticals Names New Chief Medical Officer — 8-K · Jan 13, 2025 Risk: medium
  Apellis Pharmaceuticals, Inc. announced on January 8, 2025, the departure of its Chief Medical Officer, Dr. Federico Cervera, effective January 10, 2025. The co
• SC 13G Filing — SC 13G · Nov 22, 2024
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• SC 13G Filing — SC 13G · Nov 8, 2024
• SC 13G/A Filing — SC 13G/A · Nov 8, 2024
• Apellis Pharmaceuticals Files Q3 2024 10-Q — 10-Q · Nov 5, 2024 Risk: medium
  Apellis Pharmaceuticals, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported significant financial activities and operational upd
• SC 13G Filing — SC 13G · Oct 18, 2024
• Apellis Pharmaceuticals Files 8-K Report — 8-K · Aug 8, 2024 Risk: low
  On August 8, 2024, Apellis Pharmaceuticals, Inc. filed an 8-K report. The filing indicates "Other Events" as the primary item of disclosure. No specific details
• Apellis Pharmaceuticals Files Q2 2024 10-Q — 10-Q · Aug 1, 2024 Risk: medium
  Apellis Pharmaceuticals, Inc. filed its 10-Q for the period ending June 30, 2024. The filing details financial performance and operational updates, including in
• Apellis Pharmaceuticals Files 8-K on Shareholder Votes — 8-K · Jun 5, 2024 Risk: low
  Apellis Pharmaceuticals, Inc. filed an 8-K on June 5, 2024, to report on matters submitted to a vote of its security holders. The filing does not contain specif
• Apellis Pharmaceuticals Enters Material Agreement — 8-K · May 14, 2024 Risk: medium
  On May 13, 2024, Apellis Pharmaceuticals, Inc. entered into a Material Definitive Agreement and created a direct financial obligation. The filing does not speci
• Apellis Pharmaceuticals Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 7, 2024 Risk: medium
  Apellis Pharmaceuticals, Inc. (APLS) filed a Quarterly Report (10-Q) with the SEC on May 7, 2024. Apellis Pharmaceuticals, Inc. filed a 10-Q report for the quar
• Apellis Pharmaceuticals, Inc. Files Definitive Proxy Statement — DEF 14A · Apr 26, 2024 Risk:
  Apellis Pharmaceuticals, Inc. (APLS) filed a Proxy Statement (DEF 14A) with the SEC on April 26, 2024. Apellis Pharmaceuticals, Inc. filed a Definitive Proxy St
• Apellis Pharmaceuticals Files 10-K/A Amendment — 10-K/A · Feb 29, 2024 Risk: medium
  Apellis Pharmaceuticals, Inc. (APLS) filed a Amended Annual Report (10-K/A) with the SEC on February 29, 2024. Apellis Pharmaceuticals, Inc. filed a 10-K/A (Ann
• Apellis Files 8-K on Financials and Other Events — 8-K · Feb 27, 2024 Risk: low
  Apellis Pharmaceuticals, Inc. filed an 8-K on February 27, 2024, to report on its "Results of Operations and Financial Condition," "Other Events," and "Financia
• Apellis Pharmaceuticals, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Feb 27, 2024 Risk: medium
  Apellis Pharmaceuticals, Inc. (APLS) filed a Annual Report (10-K) with the SEC on February 27, 2024. Apellis Pharmaceuticals, Inc. filed its 2023 Form 10-K on F
• SC 13G Filing — SC 13G · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 13, 2024
• Wellington Mgmt. Reports 7.0% Stake in Apellis Pharma — SC 13G/A · Feb 8, 2024 Risk: low
  Wellington Management Group LLP, a major investment firm, filed an amended SC 13G/A on February 8, 2024, indicating a change in their beneficial ownership of Ap
• Apellis Pharma Reports Executive Changes & Comp Arrangements — 8-K · Jan 22, 2024
  Apellis Pharmaceuticals, Inc. filed an 8-K on January 22, 2024, reporting events from January 16, 2024, related to changes in its executive team and compensatio
• Apellis Pharma Files 8-K on Operations & Financial Condition — 8-K · Jan 8, 2024
  Apellis Pharmaceuticals, Inc. filed an 8-K on January 8, 2024, to report on its results of operations and financial condition. This filing indicates that the co

Risk Profile

Risk Assessment: Of APLS's 19 recent filings, 1 were flagged as high-risk, 11 as medium-risk, and 7 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Apellis Pharmaceuticals, INC.'s most recent 10-Q filing (Oct 30, 2025):

• Revenue: $458.6M
• Net Income: $215.7M
• EPS: N/A
• Debt-to-Equity: N/A
• Cash Position: $479.2M
• Operating Margin: N/A
• Total Assets: N/A
• Total Debt: N/A

Key Executives

• Timothy Sullivan
• Dr. Federico Cervera
• Dr. Caroline Lohmann
• Cedric Francois
• Nur Nicholson

Industry Context

The biopharmaceutical industry is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies like Apellis operate in a competitive landscape where innovation, intellectual property protection, and successful commercialization of therapies are paramount. Trends include a focus on rare diseases, advancements in targeted therapies, and increasing scrutiny on drug pricing and market access.

Top Tags

Pharmaceuticals (4) · 10-Q (4) · pharmaceuticals (4) · Apellis Pharmaceuticals (4) · corporate-governance (3) · sec-filing (3) · Biotechnology (2) · financials (2) · quarterly-report (2) · executive-compensation (2)

Key Numbers

• Net Income (Q3 2025): $215.7M — Significant turnaround from a $57.4M net loss in Q3 2024
• Net Income (YTD Sept 2025): $81.3M — Shift from a $161.5M net loss in YTD Sept 2024
• Total Revenue (Q3 2025): $458.6M — Increased from $196.8M in Q3 2024, primarily due to licensing
• Licensing and Other Revenue (Q3 2025): $280.8M — Massive increase from $20.3M in Q3 2024, driving profitability
• Product Revenue (Q3 2025): $177.8M — Relatively stable compared to $176.6M in Q3 2024
• Net Cash from Operations (YTD Sept 2025): $59.5M — Positive cash flow from operations, compared to $107.2M used in YTD Sept 2024
• Cash and Cash Equivalents (Sept 30, 2025): $479.2M — Increased from $411.3M at Dec 31, 2024, improving liquidity
• Research and Development (Q3 2025): $68.2M — Decreased from $88.6M in Q3 2024
• Common Shares Outstanding (Oct 23, 2025): 126.5M — Reflects share activity including stock option exercises
• Net Loss for Q2 2025: $179.9M — Increased from $145.7 million in Q2 2024, indicating widening losses.
• Net Loss for H1 2025: $350.2M — Increased from $290.3 million in H1 2024, reflecting higher operational costs.
• Product Revenue for Q2 2025: $100.0M — Primarily from SYFOVRE sales, showing commercial progress.
• R&D Expenses for Q2 2025: $110.0M — Increased from $95.0 million in Q2 2024, reflecting pipeline investment.
• SG&A Expenses for Q2 2025: $150.0M — Increased from $120.0 million in Q2 2024, driven by commercialization.
• Senior Secured Credit Facility: $300.0M — Maximum available from Sixth Street Partners, providing liquidity.

Forward-Looking Statements

• {"claim":"Wellington Management Group LLP will maintain a significant, but potentially fluctuating, stake in Apellis Pharmaceuticals, Inc. for the foreseeable future.","entity":"Wellington Management Group LLP","targetDate":"December 29, 2024","confidence":"medium"}

Related Companies

SGEN · BMRN · ALXN · REGN · BIIB

Frequently Asked Questions